Fulvestrant

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4402 publications

Clinicogenomic Landscape and Function of PIK3CA, AKT1, and PTEN Mutations in Breast Cancer.

Clinicogenomic Landscape and Function of PIK3CA, AKT1, and PTEN Mutations in Breast Cancer.

Journal: JCO precision oncology

Published: April 09, 2026

Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study.

Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study.

Journal: ESMO real world data and digital oncology

Published: April 03, 2026

CDK4/6 inhibitors in invasive lobular carcinoma: Efficacy, resistance patterns, and endocrine partners.

CDK4/6 inhibitors in invasive lobular carcinoma: Efficacy, resistance patterns, and endocrine partners.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: March 24, 2026

Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial.

Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial.

Journal: JAMA oncology

Published: March 19, 2026

Patient-derived xenograft models of primary breast cancer for preclinical evaluation of neoadjuvant therapies.

Patient-derived xenograft models of primary breast cancer for preclinical evaluation of neoadjuvant therapies.

Journal: Science translational medicine

Published: March 18, 2026

Computational discovery of precision therapeutics for hidradenitis suppurativa.

Computational discovery of precision therapeutics for hidradenitis suppurativa.

Journal: bioRxiv : the preprint server for biology

Published: March 09, 2026

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 09, 2026

Impact of Time of Administration, Fasting, and a Low-Carbohydrate Diet on Alpelisib-Associated Hyperglycemia and Efficacy: A Pilot Randomized Controlled Phase IIb Trial.

Impact of Time of Administration, Fasting, and a Low-Carbohydrate Diet on Alpelisib-Associated Hyperglycemia and Efficacy: A Pilot Randomized Controlled Phase IIb Trial.

Journal: Cancers

Published: February 27, 2026

Metastatic Breast Cancer Presenting as an Organizing Pneumonia Pattern on Chest CT: A Case Report.

Metastatic Breast Cancer Presenting as an Organizing Pneumonia Pattern on Chest CT: A Case Report.

Journal: Cureus

Published: February 27, 2026

Model-based steady state pharmacokinetic predictions using high throughput cassette infusion approach in mice.

Model-based steady state pharmacokinetic predictions using high throughput cassette infusion approach in mice.

Journal: Xenobiotica; the fate of foreign compounds in biological systems

Published: February 26, 2026

Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial.

Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial.

Journal: JAMA oncology

Published: February 19, 2026

KAT6 inhibitors under investigation for solid tumors: the preclinical and early phase progress.

KAT6 inhibitors under investigation for solid tumors: the preclinical and early phase progress.

Journal: Expert opinion on investigational drugs

Published: February 17, 2026

Showing 1-12 of 4,402

Last Updated: 04/28/2026